ExodusPoint Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-65,830
Closed -$373K 2045
2024
Q4
$373K Buy
65,830
+32,834
+100% +$212K ﹤0.01% 1225
2024
Q3
$193K Buy
+32,996
New +$240K ﹤0.01% 1459
2023
Q3
Sell
-24,321
Closed -$278K 2189
2023
Q2
$278K Buy
+24,321
New +$252K ﹤0.01% 1571
2022
Q3
Sell
-10,787
Closed -$64K 2341
2022
Q2
$64K Sell
10,787
-4,803
-31% -$32.4K ﹤0.01% 1782
2022
Q1
$119K Buy
+15,590
New +$69.5K ﹤0.01% 1985
2021
Q3
Sell
-35,328
Closed -$146K 2687
2021
Q2
$146K Buy
+35,328
New +$160K ﹤0.01% 2066
2021
Q1
Sell
-12,205
Closed -$87K 2657
2020
Q4
$87K Sell
12,205
-7,351
-38% -$70.7K ﹤0.01% 1846
2020
Q3
$209K Sell
19,556
-22,160
-53% -$260K ﹤0.01% 1455
2020
Q2
$526K Buy
+41,716
New +$485K 0.01% 1061
2020
Q1
Sell
-11,100
Closed -$155K 1683
2019
Q4
$155K Buy
+11,100
New +$161K ﹤0.01% 1382

Other funds holding VYGR

ExodusPoint Capital Management's VYGR Position: Q1 2025 in Review

ExodusPoint Capital Management sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 65,830 shares — an estimated $373K sold.

ExodusPoint Capital Management first reported a position in VYGR in Q4 2019 and held it in 10 quarters. The position peaked at $526K in Q2 2020. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

  • ExodusPoint Capital Management reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 65,830 Voyager Therapeutics shares in Q1 2025, an estimated $373K.
  • ExodusPoint Capital Management first reported a position in Voyager Therapeutics in Q4 2019 and held it in 10 quarters.
  • ExodusPoint Capital Management's Voyager Therapeutics position peaked at $526K in Q2 2020.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on ExodusPoint Capital Management's 13F filing for Q1 2025, filed 14 May 2025.